5 results
The objective is to define the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group 2 to less than 12 and 12 to less than 18 years. A further objective is…
(A) Determine the influence of anger and frustration on self-reported bruxism.(B) Validation of a new ambulant electromyographic (EMG) diagnostic device for bruxism (TeleBrux).(C) Determine the additional value of peripheral modulation with…
To study the effect on intraocular pressure in patients using the Travalert dosing aid with or without the additional use of the Eyot and with of without additional patient education.
To investigate the efficacy, safety, and pharmacokinetics of volasertib in combination with low-dose cytarabine versus investigator*s choice of anti-leukemic treatment in patients with relapsed or refractory acute myeloid leukemia with no…
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low-dose cytarabine in patients * 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction…